Xencor (XE9) AI Stock Analysis

Xencor

(BX Swiss:XE9)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

XmAb platformThe XmAb platform provides a reusable antibody-engineering foundation across cancer and autoimmune or inflammatory programs. Its ability to enhance immune activity, half-life, and multispecific binding can support differentiated candidates and partnership opportunities over multiple development cycles.

Negative Factors

Persistent lossesSizable net losses and deeply negative operating results show that current development spending is not yet supported by recurring earnings. Continued losses can erode the capital base and leave future financial performance dependent on successful clinical progress, partnerships, or additional funding.

Xencor Business Overview & Revenue Model

Company Description

Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine th...

Xencor Earnings Call Summary

Earnings Call Date:Feb 26, 2024(Q4-2023)|Next Earnings Date:Nov 08, 2026

Earnings Call SentimentPositive

The earnings call presented a positive outlook with significant pipeline progress and a strong financial position. However, safety concerns with vudalimab and a strategic pause on XmAb564 development were noted.

Positive Updates

Strong Financial Position

Xencor ended 2023 with $697 million, providing runway into 2027 due to robust milestone and royalty revenues.

Negative Updates

Safety Concerns with Vudalimab

One case of Grade 5 immune-related hepatitis was reported, raising safety considerations for the treatment.

Company Guidance

During Xencor's fourth-quarter 2023 earnings call, the company provided comprehensive guidance on its clinical pipeline and financial outlook. They highlighted a significant focus on the development of bispecific T-cell engagers for solid tumors, including XmAb819 and XmAb808, with ongoing Phase I studies in renal cell carcinoma and prostate cancer, respectively. Vudalimab, a key candidate, showed promising monotherapy results in heavily pre-treated metastatic castrate-resistant prostate cancer patients, with a RECIST response rate of 35% and a PSA90 rate of 25%. Financially, Xencor bolstered its balance sheet through the partial monetization of Ultomiris and Monjuvi royalties, ending 2023 with $697 million, ensuring operational runway until 2027. The company's 2024 priorities include advancing its solid tumor bispecific programs and selecting the next IND candidate, while maintaining a strategic focus on T-cell engager discovery and development.

Xencor Risk Analysis

Xencor disclosed 56 risk factors in its most recent earnings report. Xencor reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Xencor Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:XE9 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANAB	63Neutral	$1.44B	7.15	2515.23%	―	92.92%	―
ABCL	61Neutral	$3.98B	-22.72	-17.49%	―	101.28%	2.49%
ZYME	59Neutral	$2.03B	-14.16	-72.07%	―	-69.78%	-106.07%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INBX	45Neutral	$1.06B	-8.08	1893.60%	―	-100.00%	19.23%
CTMX	43Neutral	$509.88M	-5.20	-38.46%	―	-87.03%	-179.91%

* Healthcare Sector Average

Performance Comparison

CH:XE9 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CTMX	CytomX Therapeutics Inc.	2.34	-1.75	-42.79%
ANAB	AnaptysBio	48.28	25.12	108.50%
ZYME	Zymeworks	28.61	10.45	57.54%
ABCL	Abcellera Biologics, Inc.	12.27	7.40	151.95%
INBX	Inhibrx Biosciences, Inc.	71.78	-10.21	-12.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Xencor AI Stock Analysis